LightNews LightNews
rebjul1.bsky.social
@rebjul1.bsky.social
11 followers 40 following 5 posts
Posts Replies Media Videos
Reposted
covid19disease.bsky.social
www.independent.co.uk/asia/nipah-v...
Airports reintroduce Covid-style checks after virus outbreak in India
Thailand, Nepal and Taiwan rush to detect and prevent spread of Nipah virus from travellers
www.independent.co.uk
January 26, 2026 at 1:39 PM
Reposted
sailorrooscout.bsky.social
The new nasal AIBP vaccine from Trinity College Dublin stops whooping cough in lungs and nose, hinting at true transmission blocking immunity. NOTE: This is PRECLINICAL.

The study has been published in the Nature Microbiology. YES, it is PEER-REVIEWED.
• www.nature.com/articles/s41...

🧪🧵⬇️
ABSTRACT The Gram-negative bacterium Bordetella pertussis causes whooping cough (pertussis), a severe respiratory disease, especially in young children, which is resurgent despite high vaccine coverage. The current acellular pertussis vaccine prevents severe disease but does not prevent nasal infection with B. pertussis. This parenterally delivered vaccine induces potent circulating antibody responses but limited respiratory tissue-resident memory T cells and IgA responses. Here we developed a vaccine approach based on respiratory delivery of antibiotic-inactivated B. pertussis (AIBP). Ciprofloxacin-treated B. pertussis potently activated antigen-presenting cells to drive T cell responses. AIBP immunization via aerosol or intranasal administration conferred a high level of protection against lung and nasal infection. The AIBP vaccine induced B. pertussis-specific interleukin (IL)-17-producing CD4 tissue-resident memory T cells that recruited neutrophils to the respiratory tract. Protection was abrogated by depletion of CD4 T cells or neutralization of IL-17 in mice. Unlike a parenterally delivered whole-cell pertussis vaccine, which induced high levels of serum IL-1฿, IL-6, tumour necrosis factor and C-reactive protein, aerosol immunization with the AlBP vaccine did not promote systemic pro-inflammatory responses. We present preclinical evidence of a safe and effective respiratory-delivered vaccine platform for inducing T cell-mediated sterilizing immunity against a respiratory pathogen.
January 15, 2026 at 5:02 PM
Reposted
sailorrooscout.bsky.social
controls. The team also tested AIBP as a booster for animals that had already received conventional acellular vaccines. Prior shots did not block the new response. After a mucosal AIBP boost, those animals developed the same strong local immunity and cleared infection from both lungs and nose.
January 15, 2026 at 5:12 PM
Reposted
covid19disease.bsky.social
www.cidrap.umn.edu/antimicrobia...
Novel XDR Shigella strain identified in Los Angeles
www.cidrap.umn.edu
January 15, 2026 at 5:05 PM